Addressing Solid Tumour Heterogeneity: TROCEPT-Mediated Activation of a Universal Bispecific T-cell Engager via IV Delivery
9:00 am - Thursday 9th July 2026
- Targeting tumour heterogeneity by focusing on markers expressed across all cancer cells, ensuring no malignant cell is missed
- Overcoming immune suppression with therapies potent enough to activate immune responses despite the tumour’s inhibitory environment
- Reducing off-target toxicity by restricting therapeutic activity to tumour cells, expanding the therapeutic window for safer treatment
